Breaking News Instant updates and real-time market news.

TIVO

TiVo

$12.35

0.15 (1.23%)

, AMZN

Amazon.com

$1,878.06

-3.88 (-0.21%)

13:10
08/20/18
08/20
13:10
08/20/18
13:10

Report incorrectly characterized Amazon DVR as threat to Tivo, says B. Riley FBR

B. Riley FBR analyst Eric Wold said he believes that Bloomberg's article on Friday discussing the possibility that Amazon (AMZN) is at work on a device to record and store live TV incorrectly characterized this technology/product as a threat to Tivo (TIVO). He actually believes, conversely, that it creates an additional licensing opportunity for TiVo that could push it to revisit litigation against Amazon. Wold contends that it would be "virtually impossible" for Amazon to develop an offering as described by Bloomberg without infringing upon any of TiVo's other guide, search, discovery and/or video IP beyond the company's soon-to-expire "time warp" patent. Noting further that the report comments that the functionality of the proposed Amazon DVR would be "similar to offerings from TiVo and Dish Network Corp.'s Slingbox," Wold reminds investors that Dish Network (DISH) is a licensee of TiVo. He maintains a Buy rating on TiVo shares.

TIVO

TiVo

$12.35

0.15 (1.23%)

AMZN

Amazon.com

$1,878.06

-3.88 (-0.21%)

DISH

Dish

$34.77

-0.37 (-1.05%)

  • 13

    Sep

TIVO TiVo
$12.35

0.15 (1.23%)

07/05/18
JPMS
07/05/18
NO CHANGE
JPMS
Overweight
TiVo CEO exit may be viewed as 'double edged sword,' says JPMorgan
JPMorgan analyst Sterling Auty says news of TiVo CEO Enrique Rodriguez stepping down "can be perceived as a double edged sword." On one hand, investors might perceive the transition as negative for the company's strategic review process given Rodriguez's expertise in intellectual property licensing and that his compensation structure was tied much to the performance of the stock price, Auty tells investors in a research note. On the other hand, some investors might perceive the transition as an indication that there may not be a need for a CEO post, a positive outcome of the strategic review process in terms of a possible sale of the company, the analyst adds. Shares of TiVo are down 4% to $13.30 in morning trading. Auty admits, however, that the timing of Rodriguez's departure is unusual and that it is hard to read what the possible implications are in terms of the strategic review process without more information. He has an Overweight rating on TiVo shares.
07/06/18
BWSF
07/06/18
NO CHANGE
Target $25
BWSF
Strong Buy
TiVo could bring on CEO via acquisition, says BWS Financial
While a CEO change "usually implies being prone to a takeover," TiVo "could look to do an acquisition to bring on a CEO" after Enrique Rodriguez resigned just six months into the role, BWS Financial analyst Hamed Khorsand tells investors in a research note. The strategic options TiVo is considering "creates a wide array of options for the imaginative investor," the analyst adds. He believes the greatest overhang on TiVo shares remains the lack of annual guidance and no real set goal of what free cash flow could look like this year. Khorsand sees options for the company and keeps a Buy rating on the shares with a $25 price target.
07/25/18
JPMS
07/25/18
NO CHANGE
JPMS
Overweight
Invalidated patent 'not material' to TiVo court fight, says JPMorgan
JPMorgan analyst Sterling Auty noted that the USPTO's Patent Trial and Appeal Board has declared patent 8,433,696 held by TiVo (TIVO) to be invalid as it believes that the technology involves a variation of earlier know-how. While a "scary headline," the reality is this does not matter in terms of TiVo's court case with Comcast (CMCSA), since this patent was dropped from the case, said Auty, who keeps an Overweight rating on TiVo shares.
08/09/18
JPMS
08/09/18
NO CHANGE
Target $18
JPMS
Overweight
TiVo price target lowered to $18 from $30 at JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for TiVo to $18 following the company's Q2 results but keeps an Overweight rating on the name. The analyst is "very encouraged" by the update from interim CEO Raghu Rau regarding the strategic review. The options laid out appear to make it clear that there are a couple different opportunities for shareholder value creation that potentially include breaking apart the products and intellectual property businesses to maximize the monetization potential, Auty tells investors in a post-earnings research note. He also believes TiVo pausing its search for a new CEO suggests that an outcome could take place near term.
AMZN Amazon.com
$1,878.06

-3.88 (-0.21%)

08/13/18
08/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN SACHS CUTS ALNYLAM TO BUY: Goldman Sachs analyst Terence Flynn downgraded Alnylam (ALNY) to Buy from Conviction Buy. The analyst also lowered his price target for the shares to $155 from $193. Flynn said the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. Piper Jaffray analyst Edward Tenthoff recommended buying shares of Alnylam Pharmaceuticals on weakness following the approval of Onpattro. Morgan Stanley analyst David Lebowitz lowered his price target to $93, Nomura Instinet analyst Christopher Marai lowered his price target to $73, and Stifel analyst Paul Matteis maintained a Buy rating but cut his price target to $123 from $125 and slightly lowered his revenue ramp for the drug based on modestly reduced share in mixed-phenotype haTTR patients and lower share in cardiac-only haTTR patients. B. Riley FBR analyst Madhu Kumar raised his price target to $230. RUBIUS THERAPEUTICS INITIATED AT MULTIPLE FIRMS: Rubius Therapeutics (RUBY) was initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. PIPER JAFFRAY SAYS AMAZON AD BUSINESS GROWING INTO PROFIT DRIVER: Amazon's (AMZN) advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson told investors in a research note. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contended. IMPERIAL CAPITAL CUTS NETFLIX PRICE TARGET TO $494: Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $494 after he slightly reduced his global subscriber estimates. The analyst said that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. DISH DOWNGRADED TO SELL AT MOFFETTNATHANSON: MoffettNathanson analyst Craig Moffett downgraded Dish (DISH) to Sell from Neutral with a price target of $29 and noted that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse.
08/17/18
ARGS
08/17/18
NO CHANGE
Target $112
ARGS
Buy
Walmart price target raised to $112 from $100 at Argus
Argus analyst Chris Graja raised his price target on Walmart (WMT) to $112, citing the company's decade-best Q2 comps growth and a positive update on its e-commerce business, which grew by 40% in Q1. Graja also notes that online grocery sales were strong, as the department delivered its best comps growth in 9 years to retain its competitive position against Amazon's (AMZN) Whole Foods unit. The analyst keeps his Buy rating on Walmart and contends that the company is immune to the primary risk of "irrelevance" for retailers, stating that it plays an "important" role in the economy with its buying power and "logistical prowess".
08/20/18
RBCM
08/20/18
NO CHANGE
Target $172
RBCM
Outperform
VMware to deliver 'solid quarterly results', says RBC Capital
RBC Capital analyst Matthew Hedberg kept his Outperform rating and $172 price target on VMware (VMW) ahead of its earnings, saying the recent surveys and his positive meetings with the management during the quarter suggest the company will deliver "solid" results. The analyst maintains that "VMware is well-positioned to capitalize on hybrid-cloud adoption", adding he is also looking for signs of additional growth on its core-compute platform, Dell synergies, and its Amazon (AMZN) AWS partnership.
08/20/18
LOOP
08/20/18
NO CHANGE
Target $250
LOOP
Hold
Ulta Beauty Q2 may outperform based on competitor trends, says Loop Capital
Loop Capital analyst Anthony Chukumba is keeping his Hold rating and $250 price target on Ulta Beauty (ULTA) ahead of its Q2 earnings next week, but notes that there may be some upside to his expectations based on the positive recent competitor commentary. The analyst expects investors to focus on the comparable and mass cosmetics sales growth, along with the company's operating margins and future earnings guidance, particularly in light of the slowing sequential comps growth trends over the past 6 quarters and concerns about the Amazon (AMZN) inroads in the prestige cosmetics market.
DISH Dish
$34.77

-0.37 (-1.05%)

08/13/18
08/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Rite Aid (RAD) downgraded to Market Perform from Outperform at Cowen with analyst Charles Rhyee saying shares of Ride Aid adequately reflect its outlook, following the termination of the company's merger with Albertsons. 2. Akamai (AKAM) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick saying with the stock up 29% since Elliott Management's disclosure of a stake on December 15, 2017, many of the catalysts have played out. 3. Alnylam (ALNY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. 4. Goodyear Tire (GT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying he remains "constructive" on the long-term growth for global miles traveled, but believes this will not affect the stock for the next 12 months due to the overhang from estimate achievability. 5. Dish (DISH) downgraded to Sell from Neutral at MoffettNathanson with analyst Craig Moffett saying while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
MOFT
08/13/18
DOWNGRADE
Target $29
MOFT
Sell
Dish downgraded to Sell at MoffettNathanson on deteriorating spectrum
As reported earlier, MoffettNathanson analyst Craig Moffett downgraded Dish to Sell from Neutral with a price target of $29. The analyst notes that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment - which holds "all" of the company's equity value - is worse. Moffett states that all considerations for the business aside from Spectrum sale, including the network buildout, is a negative for Dish, adding that the Q2 report has only made the "other scenarios more likely".
08/13/18
MOFT
08/13/18
DOWNGRADE
MOFT
Sell
Dish downgraded to Sell from Neutral at MoffettNathanson

TODAY'S FREE FLY STORIES

CCC

Clarivate Analytics

$13.34

-0.04 (-0.30%)

, INFO

IHS Markit

$57.51

0.12 (0.21%)

16:50
05/20/19
05/20
16:50
05/20/19
16:50
Hot Stocks
Clarivate Analytics names Jerre Stead as CEO, effective June 30 »

Clarivate Analytics (CCC)…

CCC

Clarivate Analytics

$13.34

-0.04 (-0.30%)

INFO

IHS Markit

$57.51

0.12 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:50
05/20/19
05/20
16:50
05/20/19
16:50
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson down 2.7% at $127…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

EBAY

eBay

$36.56

-0.34 (-0.92%)

16:47
05/20/19
05/20
16:47
05/20/19
16:47
Earnings
eBay VP Kristin Yetto sells over $940K shares of company stock »

eBay VP Kristin Yetto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

16:45
05/20/19
05/20
16:45
05/20/19
16:45
General news
Fed's Williams said the Fed has changed its view on the Phillips Curve relationship »

Fed's Williams said…

VNE

Veoneer

$18.89

0.02 (0.11%)

16:43
05/20/19
05/20
16:43
05/20/19
16:43
Syndicate
Veoneer files to sell $350M of common stock, $150M of convertible senior notes »

Veoneer announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    Jun

VYGR

Voyager Therapeutics

$21.87

-0.28 (-1.26%)

16:36
05/20/19
05/20
16:36
05/20/19
16:36
Hot Stocks
Voyager Therapeutics announces retirement of chief scientific officer Dinah Sah »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

16:35
05/20/19
05/20
16:35
05/20/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Ocular Therapeutix »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

HI

Hillenbrand

$38.98

0.05 (0.13%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Initiation
Hillenbrand initiated  »

Hillenbrand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Earnings
Varian Medical cuts FY19 adj. EPS view to $4.55-$4.70 from $4.60-$4.75 »

Consensus $4.70. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

MRK

Merck

$78.86

0.15 (0.19%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Hot Stocks
Merck announces Phase 3 KEYNOTE-119 trial does not meet OS primary endpoint »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Varian to acquire Cancer Treatment Services for $283M »

Varian Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Nordson CEO says 'continue to forecast organic growth' for 2019 »

CEO Michael Hilton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:32
05/20/19
05/20
16:32
05/20/19
16:32
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

REGN

Regeneron

$302.51

-2.3 (-0.75%)

, NVS

Novartis

$82.02

-0.7 (-0.85%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Regeneron, Novartis, Sanofi initiated at Credit Suisse »

Regeneron initiated with…

REGN

Regeneron

$302.51

-2.3 (-0.75%)

NVS

Novartis

$82.02

-0.7 (-0.85%)

SNY

Sanofi

$41.40

-0.53 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 23

    May

  • 31

    May

  • 14

    Jun

  • 26

    Jun

TMO

Thermo Fisher

$263.13

1.44 (0.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Thermo Fisher to invest $50M to expand bioproduction capabilities »

Thermo Fisher announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 31

    May

  • 02

    Dec

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Earnings
Nordson reports Q2 adjusted EPS $1.54, consensus $1.60 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NBIX

Neurocrine

$76.64

-2.39 (-3.02%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Neurocrine initiated  »

Neurocrine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

, TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Cohen & Steers names Paul Zettl chief marketing officer »

Paul Zettl has joined…

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

16:30
05/20/19
05/20
16:30
05/20/19
16:30
Options
Preliminary option volume of 17.5M today »

Preliminary option volume…

VRTX

Vertex

$165.71

-2.97 (-1.76%)

16:29
05/20/19
05/20
16:29
05/20/19
16:29
Initiation
Vertex initiated at Credit Suisse »

Vertex initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

16:28
05/20/19
05/20
16:28
05/20/19
16:28
Hot Stocks
Ascena Retail announces wind down of Dressbarn »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$65.85

-0.49 (-0.74%)

16:26
05/20/19
05/20
16:26
05/20/19
16:26
Initiation
Gilead initiated at Credit Suisse »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BIIB

Biogen

$230.70

1.49 (0.65%)

16:24
05/20/19
05/20
16:24
05/20/19
16:24
Initiation
Biogen initiated at Credit Suisse »

Biogen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWI

SolarWinds

$19.16

0.04 (0.21%)

16:23
05/20/19
05/20
16:23
05/20/19
16:23
Syndicate
SolarWinds files to sell 17.25M shares of common stock »

JPMorgan, Goldman Sachs,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

AMGN

Amgen

$168.36

-1.5 (-0.88%)

16:21
05/20/19
05/20
16:21
05/20/19
16:21
Initiation
Amgen initiated at Credit Suisse »

Amgen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.